{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:59:21Z","timestamp":1792299561288,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.msard.2025.106641","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T23:26:40Z","timestamp":1753399600000},"page":"106641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment outcomes in multiple sclerosis using reduced and extended interval ocrelizumab dosing"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0864-3057","authenticated-orcid":false,"given":"Antonia","family":"McLean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Arnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin Hong","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A","family":"Broadley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106641_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103505","article-title":"Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease","volume":"59","author":"AbdelRazek","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106641_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106641_bib0003","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-023-12084-4","article-title":"COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients","volume":"271","author":"Bisecco","year":"2024","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106641_bib0004","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106641_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200152","article-title":"Efficacy of rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing?","volume":"10","author":"Claverie","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106641_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241277736","article-title":"Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials","volume":"17","author":"Derfuss","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9","key":"10.1016\/j.msard.2025.106641_bib0007","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1111\/ene.15891","article-title":"Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience","volume":"30","author":"Guerrieri","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106641_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106641_bib0009","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s13311-020-00975-7","article-title":"Differential effects of fingolimod and natalizumab on B cell repertoires in multiple sclerosis patients","volume":"18","author":"Kowarik","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106641_bib0010","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2025.106641_bib0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2025.106641_bib0012","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/acn3.51732","article-title":"Real-world evaluation of ocrelizumab in multiple sclerosis: a systematic review","volume":"10","author":"Montalban","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106641_bib0013","unstructured":"Multiple Sclerosis International Federation. Atlas of MS 3rd edition 2020. Available from: https:\/\/www.msif.org\/wp-content\/uploads\/2020\/12\/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf."},{"issue":"10","key":"10.1016\/j.msard.2025.106641_bib0014","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.3390\/ijms25105353","article-title":"Clinical and immunological impact of ocrelizumab extended interval dosing in multiple sclerosis: a single-center, real-world experience","volume":"25","author":"Nasello","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2025.106641_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12974-023-02900-z","article-title":"Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis","volume":"20","author":"Rodriguez-Mogeda","year":"2023","journal-title":"J. Neuroinflammat."},{"issue":"19","key":"10.1016\/j.msard.2025.106641_bib0016","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106641_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577721","article-title":"Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis","volume":"360","author":"Sriwastava","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106641_bib0018","series-title":"Australian Public Assessment Report for Ocrelizumab","year":"2018"},{"issue":"2","key":"10.1016\/j.msard.2025.106641_bib0019","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106641_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2024-000672","article-title":"Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study","volume":"6","author":"Tran","year":"2024","journal-title":"BMJ Neurol. Open."},{"issue":"7","key":"10.1016\/j.msard.2025.106641_bib0021","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","volume":"28","author":"van Lierop","year":"2022","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:23:48Z","timestamp":1780039428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":21,"alternative-id":["S2211034825003839"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106641","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcomes in multiple sclerosis using reduced and extended interval ocrelizumab dosing","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106641"}}